All > Esophagus Cancer > Endometrial Cancer

SGN-STNV for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-Small Cell Lung Cancer+11 MoreSGN-STNV - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test the safety and effectiveness of the drug SGN-STNV for treating solid tumors.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Cervical Cancer
  • HER2 Negative Breast Cancer
  • Esophageal Cancer
  • Pseudomyxoma Peritonei
  • Colorectal Cancer
  • Stomach Tumors
  • Pancreatic Cancer
  • Ovarian Tumors
  • Endometrial Cancer
  • Gastroesophageal Junction Cancer
  • Appendiceal Adenocarcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Vabomere
1
IMS001
1
COVID-19 vaccine

Study Objectives

3 Primary · 9 Secondary · Reporting Duration: Up to approximately 3 years

Year 3
Area under the concentration-time curve (AUC)
Incidence of adverse events (AEs)
Incidence of antidrug antibodies (ADA)
Incidence of laboratory abnormalities
Maximum concentration (Cmax)
Time to maximum concentration (Tmax)
Trough concentration (Ctrough)
Up to 28 days
Incidence of dose limiting toxicities
Year 3
Duration of objective response (DOR)
Objective response rate (ORR) as assessed by the investigator per RECIST v1.1
Overall survival (OS)
Progression-free survival (PFS)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Vabomere
1
IMS001
2
COVID-19 vaccine

Trial Design

1 Treatment Group

SGN-STNV
1 of 1

Experimental Treatment

315 Total Participants · 1 Treatment Group

Primary Treatment: SGN-STNV · No Placebo Group · Phase 1

SGN-STNV
Drug
Experimental Group · 1 Intervention: SGN-STNV · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 3 years

Who is running the clinical trial?

Seagen Inc.Lead Sponsor
185 Previous Clinical Trials
61,264 Total Patients Enrolled
Suzanne McGoldrick, MDStudy DirectorSeagen Inc.
1 Previous Clinical Trials
285 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a disease indication.
You have esophageal cancer.
You have a diagnosis of either gastric cancer or GEJ carcinoma.

Who else is applying?

How old are they?
65+100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top